Lantus site tops in consumer satisfaction: study

Share this article:

The product site for Sanofi-Aventis's insulin injection Lantus received the highest mark in terms of consumer satisfaction, according to a Manhattan Research study.

The website (which features optional registration for the “Lantus Connection” community and support program) provides “real stories, real tips and real support” for diabetics, and offers “healthcare professional visit guides” in pdf form for download.

In order to join the Lantus community, consumers must input basic information, such as name, address, type of diabetes, current treatments, results from the most recent A1C test and answer several attitudinal statements. For example, registrants are asked whether their diabetes is “completely under control,” if they “feel frazzled by not being able to control my blood sugar” and if they are “interested in learning about insulin,” and whether “having to go on (having gone on) insulin means that I have failed at controlling my blood sugar.” After providing this information, consumers presumably receive a customized newsletter via email.

Other top brand sites, according to the study, are GlaxoSmithKline's Advair website and Merck's Singulair website, coming in at number two and three, respectively.

The following sites also received high consumer satisfaction levels, according to the study: Bristol-Myers Squibb's Abilify, Pfizer's Caduet, Merck's Januvia, Bayer's Mirena, AstraZeneca's Nexium/purplepill.com, Takeda's Prevacid and Wyeth's Protonix.

“While driving visitors to sites is critical, engaging and retaining them will provide the most strategic value to the brand,” said Mark Bard, president of Manhattan Research, in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.